Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
29 05 2021
Historique:
received: 02 02 2021
accepted: 13 05 2021
revised: 05 05 2021
entrez: 30 5 2021
pubmed: 31 5 2021
medline: 15 7 2021
Statut: epublish

Résumé

Cognitive deficits in individuals at risk of psychosis represent a significant challenge for research, as current strategies for symptomatic treatment are often ineffective. Recent studies showed that atypical cognitive development predicts the occurrence of psychotic symptoms. Additionally, abnormal brain development is known to predate clinical manifestations of psychosis. Therefore, critical developmental stages may be the best period for early interventions expected to prevent cognitive decline and protect brain maturation. However, it is challenging to identify and treat individuals at risk of psychosis in the general population before the onset of the first psychotic symptoms. 22q11.2 deletion syndrome (22q11DS), the neurogenetic disorder with the highest genetic risk for schizophrenia, provides the opportunity to prospectively study the development of subjects at risk for psychosis. In this retrospective cohort study, we aimed to establish if early treatment with SSRIs in children and adolescents with 22q11DS was associated with long-term effects on cognition and brain development. We included 98 participants with a confirmed diagnosis of 22q11DS followed up 2-4 times (age range: 10-32). Thirty subjects without psychiatric disorders never received psychotropic medications, thirty had psychotic symptoms but were not treated with SSRIs, and 38 received SSRIs treatment. An increase in IQ scores characterized the developmental trajectories of participants receiving treatment with SSRIs, even those with psychotic symptoms. The thickness of frontal regions and hippocampal volume were also relatively increased. The magnitude of the outcomes was inversely correlated to the age at the onset of the treatment. We provide preliminary evidence that early long-term treatment with SSRIs may attenuate the cognitive decline associated with psychosis in 22q11DS and developmental brain abnormalities.

Identifiants

pubmed: 34052829
doi: 10.1038/s41398-021-01456-x
pii: 10.1038/s41398-021-01456-x
pmc: PMC8164636
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

336

Références

Am J Psychiatry. 2020 Apr 1;177(4):298-307
pubmed: 31838871
Science. 2008 Apr 18;320(5874):385-8
pubmed: 18420937
Cell. 2021 Mar 4;184(5):1299-1313.e19
pubmed: 33606976
Cell. 2019 Sep 5;178(6):1387-1402.e14
pubmed: 31474363
Mol Psychiatry. 2020 Nov;25(11):2844-2859
pubmed: 31164700
J Clin Psychiatry. 2006;67 Suppl 9:3-8; discussion 36-42
pubmed: 16965182
Front Cell Neurosci. 2020 Apr 15;14:82
pubmed: 32351365
Science. 2003 Aug 8;301(5634):805-9
pubmed: 12907793
JAMA Psychiatry. 2015 Apr;72(4):377-85
pubmed: 25715178
Neuroimage. 2013 Nov 15;82:200-7
pubmed: 23721724
J Neurosci. 2012 Oct 10;32(41):14074-9
pubmed: 23055475
Biol Psychiatry. 2006 Jun 15;59(12):1136-43
pubmed: 16797263
Am J Psychiatry. 2020 Apr 1;177(4):291-297
pubmed: 32233682
Int Clin Psychopharmacol. 2015 May;30(3):158-66
pubmed: 25756551
Nature. 2010 Nov 11;468(7321):187-93
pubmed: 21068826
Lancet. 2012 Apr 28;379(9826):1630-40
pubmed: 22538178
Schizophr Bull. 2003;29(4):703-15
pubmed: 14989408
J Affect Disord. 2015 Jul 15;180:179-84
pubmed: 25911132
Eur J Neurosci. 2011 Jan;33(1):49-57
pubmed: 21156002
Neuroimage. 2012 Jun;61(2):397-406
pubmed: 22178817
Hum Brain Mapp. 2014 Nov;35(11):5646-57
pubmed: 24976170
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
J Child Adolesc Psychopharmacol. 2017 Feb;27(1):83-90
pubmed: 26131914
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Mol Psychiatry. 2020 Feb 3;:
pubmed: 32015465
Neuropsychopharmacology. 2018 Oct;43(11):2221-2230
pubmed: 29955151
Am J Psychiatry. 2011 May;168(5):522-9
pubmed: 21362743
Sci Rep. 2019 Apr 19;9(1):6311
pubmed: 31004120
Neurosci Biobehav Rev. 2020 Dec;119:138-167
pubmed: 32931805
J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):59-66
pubmed: 10638068
PLoS One. 2014 Jan 10;9(1):e79055
pubmed: 24427263
Psychol Med. 2018 Oct;48(14):2375-2383
pubmed: 29338796
Int J Neuropsychopharmacol. 2015 Mar 30;18(8):
pubmed: 25829180
Schizophr Res. 2004 Dec 15;72(1):21-8
pubmed: 15531404
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Nat Rev Neurosci. 2008 Dec;9(12):947-57
pubmed: 19002191
Biol Psychiatry. 2014 Mar 1;75(5):361-70
pubmed: 24011822
Am J Psychiatry. 2010 Feb;167(2):160-9
pubmed: 20048021
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Neuropharmacology. 2017 Nov;126:200-212
pubmed: 28911966
Neuropsychopharmacology. 2009 Oct;34(11):2376-89
pubmed: 19606083
Biol Psychiatry. 2015 Jul 15;78(2):135-43
pubmed: 25555483
Eur J Neurosci. 2019 Nov;50(10):3663-3673
pubmed: 31299115
Am J Psychiatry. 2020 Jul 1;177(7):589-600
pubmed: 32046535
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Sep;5(9):875-890
pubmed: 32620531
Neuropsychopharmacology. 2013 May;38(6):909-20
pubmed: 23303069
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S503-10
pubmed: 15550349
Nat Rev Neurosci. 2013 Jan;14(1):7-23
pubmed: 23254191
World Psychiatry. 2016 Oct;15(3):259-265
pubmed: 27717277
Br J Psychiatry. 2010 Sep;197(3):174-9
pubmed: 20807960
Mol Brain. 2019 Aug 5;12(1):69
pubmed: 31383032
Mol Psychiatry. 2020 Aug;25(8):1822-1834
pubmed: 29895892
Mol Psychiatry. 2020 Jul;25(7):1364-1381
pubmed: 32439846
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269
Biol Psychiatry. 2017 Jul 1;82(1):17-25
pubmed: 27832840
Neuropsychopharmacology. 2010 Jan;35(1):147-68
pubmed: 19794405
J Pediatr Psychol. 2018 Aug 1;43(7):800-813
pubmed: 29701857
Eur Neuropsychopharmacol. 2008 Apr;18(4):235-48
pubmed: 17761406

Auteurs

Valentina Mancini (V)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland. valentina.mancini@unige.ch.

Johanna Maeder (J)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland.

Karin Bortolin (K)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland.
Medical Image Processing Lab, Institute of Bioengineering, EPFL, Lausanne, Switzerland.

Maude Schneider (M)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland.
Clinical Psychology Unit for Developmental and Intellectual Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland.
Department of Neuroscience, Center for Contextual Psychiatry, Research Group Psychiatry, KU Leuven, Leuven, Belgium.

Marie Schaer (M)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland.

Stephan Eliez (S)

Developmental Imaging and Psychopathology Laboratory, Department of Psychiatry, University of Geneva School of Medicine, Geneva, Switzerland.
Department of Genetic Medicine and Development, University of Geneva School of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH